Proliferative effects of different hormone regimens on mammary glands in ovariectomized rats

Objective: To compare the proliferative effect of different hormone regimens and estrogen receptor modulation on mammary glands in a rat model of surgical menopause.

Design: Experimental animal study.

Setting: University Hospital.

Intervention: In a rat model of surgical menopause, 78 adult Sprague Dawley female rats were ovariectomized and treated with estrogen, estrogen combined with continuous or intermittent progesterone or the estrogen receptor modulator raloxifene and their respective vehicle controls. Following intraperitoneal drug administration for 20 days, rats were perfused, mammary glands were removed, tissues were processed for immunohistochemical (Ki-67) and hematoxylin-eosin staining, and investigated under light microscope.

Main outcome measure: Histopathological examination of mammary glands and Ki-67 positive cells (proliferation index).

Results: Histological examination showed dilatation in the duct cysts and vacuolization in the epithelial cells in groups receiving progestin, either intermittent or continuous. Histological findings in the raloxifene group were no different from the control group, and the atrophic terminal ductal lobular unit in adipose tissue rich stroma was similar to postmenopausal breast. In animals with a proliferative response, increased proliferation started and dominated in the terminal ductal lobular unit epithelium. Comparison of Ki-67 proliferation indices between groups revealed that estrogen alone or combined with intermittent progesterone yielded significantly higher Ki-67 indices compared to controls; estrogen combined with continuous progesterone also resulted in increasing the probability of proliferation, but the effect was not as pronounced as the other two groups. Raloxifene treatment, on the other hand, did not cause proliferation.

Conclusion: Estrogen alone or combined with progesterone may increase the risk of breast cancer by enhancing proliferation in the TDLU; raloxifen does not induce proliferation and may be a safe estrogen receptor modulator regarding its effects on mammary glands during menopause.

Hormone replacement; Rat; Mammary gland; Ki-67 antigen; Proliferation

[1] Jeng M.H., Parkere C.J., Jordan V.C.: "Estrogenic poterntial of progestins in oral contraceptives to stimulate human breast cancer cell proliferation". Cancer Res., 1992, 52, 6539.

[2] Howell A.: "Antiestrogens". Fut. Prospects Oncol., 1997, 11, 59.

[3] Levenson A.S., Jordan V.C.: "The key to antiestrogenic mechanism of raloxifene is aminoacid 351 (aspartate) in the estrogene receptor". Cancer Res., 1998, 58, 1872.

[4] Russo J., Russo I.H.: "The etiopathogenesis of breast cancer prevention". Cancer Lett., 1995, 90, 81.

[5] Gerdes J., Li L., Schluter C. : "lnununobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67" Am. J. Pathol., 1991, 138, 867.

[6] Bruno S., Darzynkiewicz Z.: "Cell cycle dependent expression and stabilty of the nuclear protein detected by Ki67 antibody in HL-60 cells". Cell Prolif., 1992, 25, 31.

[7] Kirkwood T.B.L.: "Comparative and Evolutionary aspects of Longevity". New York, Van Nostrand Reinhold, 1985.

[8] Sadi M.V., Barrack E.R.: "Determination of growth fraction in advanced prostate cancer by Ki-67 immumstaining and its relationship to the time to tumor progression after hormonal therapy". Cancer, 1991, 67, 3065.

[9] American Cancer Society, cancer facts & figures http://www.cancer.org/statistics.htlm.

[10] Ross R.K, Paganini-Hill A., Wan P.C., Pike M.C.: "Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin". J. Natl. Cancer Inst., 2000, 92, 328.

[11] Magnusson C., Baron J.A., Correia N., Bergstrom R., Adami H.O., Persson I.: "Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy". Int. J. Cancer, 1999, 81, 339.

[12] Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R.: "Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk". J. Am. Med. Assoc., 2000, 283, 485.

[13] Santen R.J., Pinkerton J., McCartney C., Petroni G.R.: "Risks of breast cancer with progestins in combination with estrogen as hormone replacemnt therapy". J. Clin. Endocrinol. Metab., 2001, 86, 1623.

[14] Million Women Study Collaborators: "Breast cancer and hormone replacement therapy in the Million Women Study". Lancet, 2003, 362, 419.

[15] Writing Group for the Women's Health Initiative Investigators: "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial". J. Am. Med. Assoc., 2002, 288, 321.

[16] Speroff L.: "Postmenoposal hormone therapy and the risk of breast cancer. A clinician's view". Eur. Men. J., 2004, 49, 51.

[17] Gompel A., Chaouat M., Hugo! D., Forgez P.: "Steroidal hormones and proliferation, differentiation and apoptosis in breast cells". Eur. Men. J., 2004, 49, 16.

[18] WHI: "Risks and benefits of estrogen plus progestin healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial". J. Am. Med. Assoc., 2002, 288, 321.

[19] Soderqvist G., von Schoultz B.: "Lessons to be learned from clinical studies on hormones and the breast". Maturitas, 2004, 49, 90.

[20] Pike M., Spicer D., Dahmoush L., Press M.F.: "Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk". Epidemiol. Rev., 1993, 15, 17.

[21] Haslam S.Z., Osuch J.R., Rafaat A.M., Hofseth L.J.: "Postmenopausal hormone replacement therapy: Effects on normal mammary gland in humans and in a mouse postmenopausal model". J. Mam. GI. Biol. and Neo, 2002, 7, 93.

[22] Johansson C.M., Anderson T.J., Bergstrom R., Lindgren A., Persson I.R.: "Epithelial proliferation in the normal human breast in relation to endogenous hormones and oral contraceptive use". Breast J., 1998, 7.

[23] Lignieres B.: "Effects of progestogens on the postmenopausal breast". Climacteric., 2002, 5, 229.

[24] Spicer D.V., Pike M.C.: "The prevention of breast cancer through reduced ovarian steroid exposure". Acta Oneal., 1992, 31, 167.

[25J Soderzvist G., Olsan H., W心ng N., von Schoultz B., Carlstrom K.: "Metabolism of estrone sulphate by normal mammary gland. Influence of menopausal status and oral contraceptives". J. Steroid. Biochem. Mo/. Biol., 1997, 18, 221.

[26] Kutter F., Malet C., Leygue E.: "Antioestrogen action of progestogens in human breast" In: Berg G., Hammar M. (eds.). The Modern Management of Menopause. Proceedings of the 7'" Int. Congress on the Menopause, London, Parthenon, 1993, 419.

[27] Persson I., Weiderpass E., Bergkvist L., Bergstrom R., Schairer C.: "Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement". Cancer Causes Control, 1999, 10, 253.

[28] Seeger H., Wallwiener D., Mueck A.O.: "Comparison of the effect of progesterone, medroxyprogesterone acetate and norethisterone on the proliferation of human breast cancer cells". J. Br. Menopause Soc., 2003, 9, 36.

[29] Hofseth L.J., Raafat A.M., Osuch J.R., Pathak D.R., Slomski C.A., Haslam S.Z.: "Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast". J. Clin. Endocrinol. Metab., 1999, 84, 4559.

[30] Scholzen T., Gerdes J.:'The Ki-67 Protein: from the known and the unknown". J. Cell. Physiol., 2000, 182, 311.

[31] Raafat A.M., Hofseth L.J., Haslam S.Z.: "A mouse model to study the proliferative effects of hormone replacement therapy on normal postmenopausal mammary gland: Proliferative effects of combined estrogen and progestin treatment". Am. J. Obstet. Gynecol., 2001, 184, 340.

[32] Hargreaves D.F., Knox F., Swindell R., Potten C.S., Bundred NJ. "Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy". Br. J. Cancer, 1998, 78, 945.

[33] Katzenellenbogen B.S., Katzenellenbogen J.A.: "Bio-medicine. Defining the'S'in SERMs". Science, 2002, 295, 2380.

[34] Sporn M.B., Dowsett S.A., Mershon J., Bryant H.U.: "Role of raloxifene in breast cancer prevention in postmenopausal women: clinical Evidence and potential mechanisms of action". Cli. Therapeutics, 2004, 26, 830.

[35] Dowsett M., Bundred NJ., Decensi A.: "Effect of raloxifene on breast cancer cell Ki-67 and apoptosis: A double-blind, placebocontrolled, randomized clinical trial in postmenopausal patients" Cancer epiderniol biornarkers prev., 2001, 10, 961.

[36] Cauley J.A., Norton L., Lippmann M.E.: "Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation (published correction appears in Breast Cancer Res. Treat., 2001, 67, 191)". Breast Cancer Res. Treat., 2001, 65, 125.